he Clinical Trials Transformation Initiative (CTTI) identifies and promotes practices to increase the quality and efficiency of clinical trials through projects that generate empirical data on how trials are currently conducted, leading to recommendations for improvement.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Landray, M. J. et al. Clinical trials: rethinking how we ensure quality. Drug Inf. J. 46, 657–660 (2012).
Archdeacon, P. et al. Optimizing expedited safety reporting for drugs and biologics subject to an investigational new drug application. Ther. Innov. Regul. Sci. 48, 200–207 (2013).
US FDA. Investigational new drug safety reporting requirements for human drug and biological products and safety reporting requirements for bioavailability and bioequivalence studies in humans. Fed. Regist. 75, 59935–59963 (2010).
Menikoff, J. The paradoxical problem with multiple-IRB review. N. Engl. J. Med. 363, 1591–1593 (2010).
Flynn, K. E. et al. Using central IRBs for multicenter clinical trials in the United States. PLoS ONE 8, e54999 (2013).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
R.M.C has received research grants from Amylin, Bristol-Myers Squibb, Eli Lilly, Janssen Research and Development, Merck and Novartis, and consultancy fees from Medscape, Amgen and Novartis. He also has ownership interest in N30 Pharma and Portola. P.T., L.M. and P.A. declare no competing interests.
Supplementary information
Supplementary information S1 (figure)
Clinical Trial Transformation Initiative member organizations (PDF 167 kb)
Related links
Related links
FURTHER INFORMATION
European Medicines Agency. Reflection paper on risk based quality management in clinical trials
Rights and permissions
About this article
Cite this article
Tenaerts, P., Madre, L., Archdeacon, P. et al. The Clinical Trials Transformation Initiative: innovation through collaboration. Nat Rev Drug Discov 13, 797–798 (2014). https://doi.org/10.1038/nrd4442
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd4442
This article is cited by
-
Clinical trial design and recommendations: collectively, we can take them
Clinical and Experimental Medicine (2018)
-
Widening the path and window of opportunity for FDA approval of non-vitamin K oral anticoagulant specific antidotes and reversal agents
Journal of Thrombosis and Thrombolysis (2016)